Coronary Embolic Protection Device Market Size, Share & COVID-19 Impact Analysis | Global | 2023-2029 | MedCore |

The global embolic protection device market is projected to experience a decline in market value over the forecast period. In 2022, the market was valued at $80 million, and by 2029, it is estimated to reach $73 million. This indicates a negative compound annual growth rate (CAGR) of -1.4%. The anticipated decrease in market value suggests potential challenges or factors impacting the demand and adoption of embolic protection devices during the forecast period.

GLOBAL CORONARY EMBOLIC PROTECTION DEVICE DATA INCLUDED:

• Unit Sales, Average Selling Prices, Market Size & Growth Trends
• Procedure Volumes
• Market Drivers & Limiters
• Market Forecasts Until 2027, and Historical Data to 2017
• Recent Mergers & Acquisitions
• Disease Overviews and Demographic Information
• Company Profiles, Product Portfolios, and SWOT for Top Competitors

PROCEDURE VOLUMES

Through our research on the global coronary embolic protection device market, iData Research has conducted a thorough analysis of procedure volumes related to angiography, angioplasty (or PCI), atherectomy, and catheterization. This meticulous examination allows us to enhance the accuracy of our market sizing and provide comprehensive procedure volume data spanning a 10-year range across 70 countries. By incorporating procedure volumes into our analysis, we aim to provide you with a comprehensive understanding of the market dynamics and trends related to coronary embolic protection devices.

GLOBAL CORONARY EMBOLIC PROTECTION DEVICE MARKET INSIGHTS

The use of embolic protection devices (EPDs) in interventional cardiology procedures has been limited due to the associated cost burden. This has resulted in physicians shifting away from utilizing EPDs, which in turn affects unit sales. EPDs are not deemed essential devices in interventional cardiology and may not always be covered under national reimbursement schedules. Consequently, the adoption of these devices is not expected to see significant growth, leading to a modest decline in the market.

MARKET SHARE INSIGHTS

The global coronary embolic protection device market was dominated by three key players: Boston Scientific, Medtronic, and Abbott. These companies held significant market share and played a crucial role in shaping the industry.

In 2022, Boston Scientific emerged as the leading competitor in the global coronary embolic protection device market. Their product offerings, such as the FilterWire EZ™ and SENTINEL™ Cerebral Protection System, contributed to their market dominance.

Medtronic held the second position in the coronary EPD market in 2022, with their Mo.Ma™ Ultra proximal cerebral protection device.

Abbott, as the third-leading competitor, offered the RX Accunet® embolic protection systems specifically designed for carotid interventions, featuring rapid exchange delivery.

These three companies played a significant role in driving innovation and competition within the coronary embolic protection device market.

RESEARCH REGIONAL COVERAGE

Throughout this research series, iData Research has covered over 70 countries across the globe in great detail. The regions covered include:

• North America (the United States and Canada),
• Latin America (Brazil, Mexico, Colombia, Argentina, Peru, Chile, Venezuela, and Other),
• Western Europe (Germany, France, Italy, Spain, Switzerland, Austria, Portugal, Benelux, Scandinavia, and Other),
• Central and Eastern Europe (Poland, Turkey, Russia, Greece, Czech Republic, Croatia, Bulgaria, Ukraine, Kazakhstan, Hungary, Romania, Baltic States (Estonia, Latvia, and Lithuania), and Other),
• Middle East (Saudi Arabia, UAE, Israel, Iran, Kuwait, Qatar, Bahrain, Oman, and Other),
• Asia Pacific (China, Japan, South Korea, India, Australia, Singapore, Indonesia, Malaysia, Thailand, the Philippines, Brunei, Myanmar, Cambodia, Vietnam, New Zealand, Taiwan, Hong Kong, and Other),
• Africa (South Africa, Egypt, Morocco, Ghana, Nigeria, Libya, Sudan, Uganda, Kenya, and Other)